CL2022001015A1 - Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos. - Google Patents

Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos.

Info

Publication number
CL2022001015A1
CL2022001015A1 CL2022001015A CL2022001015A CL2022001015A1 CL 2022001015 A1 CL2022001015 A1 CL 2022001015A1 CL 2022001015 A CL2022001015 A CL 2022001015A CL 2022001015 A CL2022001015 A CL 2022001015A CL 2022001015 A1 CL2022001015 A1 CL 2022001015A1
Authority
CL
Chile
Prior art keywords
imidazopyrimidine
relief
prevention
treatment
cognitive disorders
Prior art date
Application number
CL2022001015A
Other languages
English (en)
Inventor
Jin Yong Chung
Chan Mi Joung
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2022001015A1 publication Critical patent/CL2022001015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

US0 DE COMPUESTOS DE IMIDAZOPIRIMIDINA O IMIDAZOTRIAZINA PARA LA PREVENCION, ALIVIO O TRATAMIENTO DE TRASTORNOS COGNITIVOS Y COMPOSICION FARMACEUTICA QUE LOS COMPRENDE.
CL2022001015A 2019-10-21 2022-04-21 Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos. CL2022001015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190130384 2019-10-21

Publications (1)

Publication Number Publication Date
CL2022001015A1 true CL2022001015A1 (es) 2023-12-15

Family

ID=75619896

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001015A CL2022001015A1 (es) 2019-10-21 2022-04-21 Uso de compuestos de imidazopirimidina o imidazotriazina para prevención, alivio o tratamiento de trastornos cognitivos.

Country Status (13)

Country Link
US (1) US20220370461A1 (es)
EP (1) EP4049662A4 (es)
JP (1) JP7504203B2 (es)
KR (1) KR20220087474A (es)
CN (1) CN114929230A (es)
AU (1) AU2020370958A1 (es)
BR (1) BR112022007491A2 (es)
CA (1) CA3155209A1 (es)
CL (1) CL2022001015A1 (es)
IL (1) IL292276A (es)
MX (1) MX2022004741A (es)
WO (1) WO2021080312A1 (es)
ZA (1) ZA202204136B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723332B2 (en) * 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
WO2007023242A1 (en) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
WO2008027812A2 (en) * 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
CA2830220A1 (en) 2011-03-15 2012-09-20 Vanderbilt University Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
JP2016132660A (ja) * 2015-01-22 2016-07-25 大日本住友製薬株式会社 新規イミダゾピリミジンおよびその医薬用途
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物

Also Published As

Publication number Publication date
EP4049662A1 (en) 2022-08-31
BR112022007491A2 (pt) 2022-07-12
AU2020370958A1 (en) 2022-06-09
US20220370461A1 (en) 2022-11-24
CN114929230A (zh) 2022-08-19
KR20220087474A (ko) 2022-06-24
ZA202204136B (en) 2022-12-21
IL292276A (en) 2022-06-01
MX2022004741A (es) 2022-05-16
JP7504203B2 (ja) 2024-06-21
WO2021080312A1 (ko) 2021-04-29
EP4049662A4 (en) 2023-11-01
JP2022553323A (ja) 2022-12-22
CA3155209A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
UY38403A (es) Moduladores de la alfa-1 antitripsina
PH12020551934A1 (en) Magl inhibitors
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
PH12019501097A1 (en) Magl inhibitors
CL2012001762A1 (es) Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve.
PH12019501102A1 (en) Magl inhibitors
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
CO2020015377A2 (es) Moduladores de la expresión de apol1
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112022000855A2 (pt) Moduladores de nlrp3
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
PE20210109A1 (es) Moduladores de la expresion de irf4
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
BR112021014566A2 (pt) Moduladores de gpr35